Drawing for LUNDBECK INSTITUTE

USPTO serial 98553547

LUNDBECK INSTITUTE

Reviewed by CopyMark Law Group

Reg. 7814487Status 700Registered
Filing date
Status date
Registration date
Jun 3, 2025
Examiner
BARREDA, AMBER KYLEE
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with LUNDBECK INSTITUTE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maren C. Perry

Maren C. Perry King & Spalding LLP1185 Avenue of the AmericasNew York, NY 10036United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated by or acting on the central nervous system; pharmaceutical preparations and substances, for the treatment of disorders and diseases acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; pharmaceutical preparations and substances for the prevention and treatment of dementia, Alzheimer's disease and disorder, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood swings, psychosis, anxiety, apathy, epilepsy; pharmaceutical preparations and substances for the prevention and treatment of Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disease and disorder, insomnia, Parkinsons disease and disorder, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and suffering, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourettes syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, drowsiness, nausea, migraine, pain, alcoholism and addiction; diagnostic preparations, substances, reagents and agents for medical purposesACTIVE—
009Downloadable electronic publications, namely, books, reports, brochures, booklets, leaflets, patient information leaflets, magazines, journals, teaching and educational material in the field of pharmaceutical research and development, disease awareness, medical clinical studies, pharmaceutical tests and trials, diagnostic medicine, medicine, pharmaceuticals, disorders, diseases, clinical or medical treatment and prevention; downloadable and recorded computer software for creating searchable databases of medical and pharmaceutical information, education, namely, educational software featuring instruction in medicine and sales activities, namely, software for others for use in sales management; downloadable and recorded computer software for analyzing medical and pharmaceutical information and disease awareness; software, namely, downloadable and recorded application software for mobile devices in the nature of mobile phones, namely, software for analyzing medical and pharmaceutical information; apparatus and instruments, namely, downloadable computer software for analyzing medical and pharmaceutical information in the field of research and development, science, clinical studies, medical clinical tests and trials, diagnostic, medicine, pharmaceuticals, disorders, diseases, treatment and prevention; electronic downloadable publications, namely, magazines, journals, teaching and educational materials in the field of pharmaceutical research and development, science, medical clinical studies, pharmaceutical tests and trials, diagnostic medicine related to clinical or medical treatment and prevention; downloadable and recorded application software for mobile devices in the nature of mobile phones, namely, software for the assessment of cognitive functions; downloadable computer software for the assessment of cognitive functions; downloadable and recorded computer software for use in diagnosing, managing, monitoring, assessing, controlling and examining psychiatric and neurological disorders and diseases, dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, migraine, pain, alcoholism and dependency on drugs, alcohol, nicotine and caffeineACTIVE—
016Printed publications, namely, books, reports, brochures, booklets, leaflets, patient information leaflets, magazines, records in the nature of informational sheets, educational and training materials for research and development, science, clinical studies, tests and trials, diagnostics, medicine, drugs, disorders, diseases, treatment and preventionACTIVE—
038Arranging and conducting an online forum in the field of pharmaceuticals, disease awareness and treatments; providing online chat rooms and electronic bulletin boards for transmission of messages among computer users in the field of pharmaceuticals, disease awareness and treatmentsACTIVE—
041Educational services, namely, conducting seminars in the field of pharmaceuticals and disease awareness; providing of training in the nature of conferences, courses, seminars and workshops in the field of pharmaceuticals and disease awareness; arranging and conducting seminars, conferences, symposiums, training workshops and courses in the field of pharmaceuticals and disease awareness; educational training services in the nature of conferences, courses, seminars and workshops in the fields of pharmaceutical research and development, medical clinical studies, pharmaceutical tests and trials and diagnostic medicine related to the treatment and prevention of diseases and disorders; providing the aforementioned services electronically in the nature of online and non-downloadable, on-line, via cable and Internet and other electronic media, namely, podcasts, audio and visual media; arranging and conducting expert forums, namely, on-line training programs in the field of pharmaceuticals; providing online, non- downloadable publications, namely, books, reports, brochures, booklets, leaflets, patient information leaflets, magazines, journals, teaching and educational material in the field of pharmaceutical research and development, science, medical clinical studies in the field of pharmaceutical tests and trials, diagnostic medicine, pharmaceuticals, disorders, disease awareness, treatment and prevention related to the assessment of cognitive functions; providing educational assessment services in the field of cognitive functions through on-line non- downloadable screening toolsACTIVE—
042Pharmaceutical research and development; scientific and technological services, namely, scientific testing and research related to medical disorders, medical diseases and medical prevention; scientific and technological services, namely, scientific testing and research related to the central nervous system and central nervous system related disorders, pharmaceuticals and disease awareness; medical and clinical research, namely, pharmaceutical clinical research and conducting clinical trials for others in the field of pharmaceuticals; diagnostic research and tests, namely, providing diagnostic services for others for scientific research purposes in the field of pharmaceutical researchACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 3, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jun 3, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 15, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 15, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 9, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 18, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 19, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 19, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 19, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 4, 2024GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 4, 2024GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 4, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 2, 2024DOCKASSIGNED TO EXAMINER—
Nov 18, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 16, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance